Background: Diaspirin cross-linked hemoglobin (DCLHb) has demonstrated a pressor effect that could adversely affect traumatic hemorrhagic shock patients through diminished perfusion to vital organs, causing base deficit (BD) and lactate abnormalities. Methods: Data from two parallel, multicenter traumatic hemorrhagic shock clinical trials from 17 US Emergency Departments and 27 European Union prehospital services using DCLHb, a hemoglobin-based resuscitation ftuid. Results: In the 219 patients, the mean age was 37.3 years, 64% of the patients sustained a blunt injury, 48% received DCLHb resuscitation, and the overall 28-day mortality rate was 36.5%. BD data did not differ by treatment group (DCLHb vs. normal saline [NS]) at any time point.
D espite optimal resuscitation efforts, patients sustaining traumatic hemorrhagic shock have had an unacceptably high mortality rate. The search for a hemoglobin-based oxygen carrier (HBOC) that could be used as a resuscitation fluid both in the battlefield and civilian settings has as of yet not produced a solution that improves outcome. 1 · 3 Many of these solutions have demonstrated a pressor effect that is manifested by increased blood pressure (BP). 4 · 1 S The study of diaspirin cross-linked hemoglobin (DCLHb) in traumatic hemorrhagic shock patients included two parallel studies in the US Emergency Departments and in the European Union (EU) prehospital setting. 16 · 17 In the US study, DCLHb resuscitation was associated with increased mortality, and in the EU study, DCLHb was not associated with improved patient outcomes. 14 Resuscitation BPs from these two studies did not demonstrate a consistent DCLHb pressor effect. 18 Despite this lack of observed pressor effect, DCLHb and other HBOCs could have a deleterious effect on patient outcome if these solutions adversely alter perfusion to vital organs as manifested by a worsening of serum base deficits (BDs) and elevated lactate levels, both of which have been shown to correlate with morbidity and mortality in traumatic hemorrhagic shock.1 9 ·3J This study determined if DCLHb use in traumatic hemorrhagic shock resuscitation was correlated with BD and lactate (LA) abnormalities based either on treatment group (DCLHb vs. normal saline [NS] ) or on patient outcome (28-day mortality). The presence or absence of any adverse perfusion effects based on treatment group will provide a better understanding if the suspected pressor effect of solutions such as DCLHb should limit future study of the HBOCs in the setting of uncompensated traumatic hemorrhagic shock.
METHODS
The clinical trials of DCLHb in traumatic hemorrhagic shock occurred between February 1997 and January 1998 in the US study, and from July 1997 to May 1998 in the EU study.t6,t7 Because of an observed increased mortality in the DCLHb-treated patients in the US study, the study was terminated by the Data Safety Monitoring Board after the enrollment of 98 patients. At that time, the EU study was also halted and analysis of the EU data demonstrated no benefit with the use of DCLHb, resulting in the final termination of this EU study after the enrollment of 121 patients. The database for the cutTen! anal ysis of BDs and lactic acid levels after DCLHb use in traumatic hemorrhagic shock came from the original datasets that were collected by Baxter HcalthCare for the US and EU stud ies. BD data were ob- (36.5) tained at five-time points in both the US Emergency Department and EU prchospital studies and are reported in milliequivalent per liter. In the US trial, serum lactate levels were also obtained at five-t ime points and are reported in milligram per deciliter (mg/%). Data presented are mean va lues :!: SO for all patients based on treatment group (DCLHb vs. NS) and 28-day outcome status (survived vs. expired).
The stat ist ical analysis of the BD and lactic acid data included the comparisons of mean and SO data and the distributions of these two perfusion markers. Regression analysis was used to test the association among BD, lactate, the usc of DCLHb, and other demographic and clinical variables at each of the five-time points.
The protocols used in US and EU cl inica l tria ls were approved by the insti tutional review board of each participating institution before the enrollment of any subjects. Trials were conducted in compliance with all regulations for good cli nica l trials and practi ce. The US study was cond ucted under federal regulations governing emergency research with an exception to informed consent. The current analysis of the data was conducted with insti tuti onal review board approval from the Uni versity of Illinois at Chicago.
RESULTS
There were a total of 219 patients studi ed, with 45% coming from the US Emergency Departm ent study (Table I ). The mean age was 37.3 years, 64% of the patients sustained a blunt injury, 48% received DCL Hb resusci tation, and the overall 28-day mortality rate was 36.5%.
When analyzed by survival status in the combined US and EU dataset, BD was significantly greater in patients who died when compared with those who surv ived at the firs t four-t ime points: BD I ( -1 3.0 vs. 
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In the US clinical trial , BD did not differ by treatment group at any time point (Fig. 2, A) . No differences in BD based on treatment group were observed in either those who survived or those who died from the hemorrhagic shock (Fig.   3 , A and 8 , Table 2 ).
When s trati fying the US BD data into four ranges (>0, 0 to -4.9, -5.0 to -9.9, and -10 mEq/L or worse) and into dichotomous BD ranges ( < -4.9 vs. -5 mEq/L or worse), there were no BD differences at any of the five-time points based on treatment group (Table 3) . The overall BD distributions were noted to be different based on 28-day survival status at the first, third, and fourth time points. The distributions were a lso noted to be d ifferent based on survival s tatus when dichotomized to < -4.9 vers us -5 mEq/ L or worse at the first and th ird time points.
In the EU prehospital clinical tria l, BD again did not differ by treatment group at any time point (Fig. 2, B ). No differences in BD based on treatment group were observed in 1160 either those who survived or those who died from the hemorrhagic s hock ( Fig. 4 , A and 8 , Table 4 ).
When stratify ing the EU BD data in to four ranges (>0, 0 to -4.9, -5.0 to -9.9, and -I 0 mEq/L or worse) a nd into dichotomous BD ranges ( < -4.9 vs. -5 mEq/L or worse), there were no BD differences at any of the fi ve-time points based on treatment group (Table 5 ). The overall BD distribut ions were noted to be different based on 28-day survival status at every time point. The d is tribut ions were a lso noted to be different based on survival s ta tus when d ichotomized to < -4.9 versus -5 mEq/L or worse at the first, third, fourth, and fifth time points.
Lactate values in the US study were comparable in the two treatment groups in all but the second time point, which occurred at an average of 519 minutes a ft er the in fus ion of DC LH b or the NS control solution ( Fig. 5, B ). In the US study, lactate values did not differ based on survival status in both of the DCLH b and NS treatment groups (Fig. 6 , A and 8 , Table 6 ). When strati fying the US lactate data into five ranges (> 90, 61-90,3 1-60, 10-30, and < 10 mg/dL) and into dichotomous lactate ranges (;:::::45 and < 45 mg/dL), there were no differe nces at any of the five-time points based o n treatment group . The overall lactate distributions were noted to be different based on 28-da y survival stat us at each time point (Table 7) . The distributions were also noted to be different based on survival status when dichotomized to ;:::::45 mg/dL and < 45 mg/dL at the first, second, third, and fourth time poi nts.
Regression ana lys is did not demonstrate any relationship between treatment group and the observed BD or lactate values from either st udy except at the second time point fo r lactate in the US study where DCLHb patients had a lactate level of 49 mg/dL ± 32 mg/dL and NS resuscitated patients had a lactate level of 34 mg/dL ± 24 mg/dL. Otherwise, the observed BD and lactate values were more likely to be related to clinically relevant variables such as Glasgow Coma Scale, Injury Severity Score, mechanism of injury, Revised Trauma Score, time to study entry, total amount of blood transfused, or the preinfusion Hb level.
DISCUSSION
Development of a HBOC that could improve traumatic hemorrhagic shock patient outcomes both in the civilian and military setting continues despite previous setbacks. 3 4 -40 There is a continuing effort to develop a solution that can be carried by medics or paramedics that is stable at room temperature and could be easily used in a broad population of traumatic hemorrhagic shock patients. The use of DCLHb and other oxygen-carrying hemoglobin solutions with a pressor effect could possibly hinder successful patient resuscitation through impaired perfusion to vital organs and a worsening acid/base balance with worsening BDs and higher lactate levels. 2 -31 · 47 These products could, as a result of an adverse pressor effect, alter perfusion to vital organs in a way that could cause the occurrence of multisystem organ failure after the acute resuscitation, which would then increase mortality during the first 28 days.20.24-26,32.4s-n The suspected HBOC pressor effect could also complicate the resuscitation of traumatic hemorrhagic shock patients because systolic BP (SBP) elevations with HBOC use lead clinicians to under-resuscitate these patients, either with crystalloids or with blood, causing worsening perfusion over time due to inadequate intravascular volumes, again leading to worsening BDs and higher lactate concentrations. Although this is a post-hoc ana lysis from studies conducted over I 0 years ago, these data arc still important to further research into HBOCs because BD and lactate derangements are critical considerations during blood substitute © 2010 Lippincou William s & Wilkins clinicaltrials.t. 1 H The lack of an observed BD or lactate effect in the DCLHb clinical tri als supports further HBOC clinical trials that search to obtain a safe and efficacious product. The use of these two DCLHb studies as a model for perfusion effects is an important one, given that this pure tetrameric DCLHb solution was tested as a therapeutic because of its consistent pressor effect and purported improved perfusion to vital organs.I3. 4 I.S 4 Although pressor effects are thought to be more consistently observed with DCL Hb, a pure soluti on of hemoglobin tetramcr, these pressor effects might also occur with other hemoglobin solutions, such as HBOC-20 I, PolyHeme, or Hemolink, such that the risk of a worsening acid/base balance must be studied first using the data from these two DCLHb traumatic hemorrhagic shock clinical trials.s.Jo.42.ss-6t HBOCs have exhibi ted pressor effects thought to be due to nitric oxide scavenging. 11 · 45 • 62 Nitric oxide is a key vasodilator in the bloodstream, wh ich is synthesized by blood vessel wa ll endothelial cells and aids in stimulating the relaxation of nearby smooth muscle cclls. 63 DCLHb is a pure tetramcric hemoglobin solution thought to have the greatest pressor effect of the clinicall y tested HBOCs. Other HBOCs
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Died Survived such as PolyHeme, which are composed of mostly nontetrameric hemoglobin molecules, have been suggested to have less of a pressor effect. Despite different chemical modifications, such as synthesis with glutaraldehyde, a-raffinose, activated dextran, and molecular cross-linking, all HBOCs have been shown to exhibit some hemodynamic effects resulting from likely endothelial nitric oxide scavenging. 64 Regardless of the differences of the hemoglobin solutions with regard to pressor effects, the absence of adverse pressor effects with DCLHb use suggests that all HBOCs may be safely used in the treatment of traumatic hemorrhagic shock patients, especially if these effects are thought to be related to the presence of pure tetrameric Hb. 12 As has been seen previously, patients who ultimately died in these clinical trials had more derangements in their BDs and lactates, illustrating worsened perfusion. 10 The important question related to the use of HBOCs is whether any proposed pressor effect will be the cause of worsened perfusion, abnormal acid/base status, and higher mortality. BP effect analysis of DCLHb, patients who died did not exhibit elevated BPs. 18 Elevated BPs were actually more often observed in patients who survived. As such, there is no suggestion of a significant correlation between DCLHbinduced elevated BPs and worsened BDs and lactates, suggestive of poor perfusion. If there is no clinically measurable acid/base imbalance due to impaired perfusion with DCLHb use from these studies, it might be possible to infer that perfusion problems will also not be observed with the other hemoglobin solutions that are studied for use in the resuscitation of traumatic hemorrhagic shock patients. The use of patient data from both the US and EU studies effectively balances the study of shock in penetrating and blunt trauma victims, as well as those who had minimal fluid resuscitation in the prehospital setting before DCLHb use (EU protocol) and those with the infusion of crystalloids by Emergency Medical Services (EMS) paramedics before ----r--~------------------------------------------------------~ c, ~ 80 +----r--4-------~r-------------------------------------------- 
c;, DCLHb usc (US protocol). 13 The patients in this study arc si milar in mechanism of injury, inj ury severity, and mortality rate to trauma populations from other traumatic hemorrhagic shock studics. 6 H 7 80 and lactate elevations were correlated with patient outcome in these trials, consistent with data that suggest that worse 80s are assoc iated with higher mortality in traumat ic hemorrhagic shock. 22 · 2 •· 26 · 2 S· 52 · 6 S· 7 1 The data from these studies also confirm the mortality predicting power of 80 and lactate leve ls in traumatic hemorrhagic shock patients. 6 As such, the potential adverse effect of DCLHb treatment on perfusion can be ana lyzed by measuring BDs and lactates during the shock resuscitation.
There were no di fferences in 80 mean values or distributions both in the US and in the EU studies based on treatment group. 3 This suggests that there were no adverse perfusion effects to vital organs with the usc of DCLHb, a finding that is consistent wi th the lack of observed BP effects from these two clinical trials. 1 x The FDA concern that the vasoacti vity and potential toxicity of HBOCs are the cause of worsened patient outcome due to impaired perfusion is not supported by the data from these two DCLHb cl inical trials.
• BD and lactate levels, which correlate wi th perfusion, demonstrated no difference based on treatment with DCLHb. 5 Freilich et al., 72 in an orthopedic clinical trial, also found no difference in vasoactivi ty with a hemoglobin solution, HBOC-20 I, in young, stab le trauma patien ts who experienced a hypotensive episode.
There were also no observed di ffcrences in the mean lactate or the distribution of lactates in the US study based on treatment group. This aga in suggests that there were no adverse perfus ion effects to vital organs with the use of DCLHb, even though mortality rates were higher in patients treated with DCLHb in this study.'" As wi th the BD findings, there were lactate differences based on patient outcome, consistent with data that suggest that higher lactate levels are associated with higher mortality in traumatic hemorrhagic shock patients. 2 6 M. 7 0. 7 3· 76 Because HBOCs have been observed to reduce the measured lactate levels, it is possible that the lack of observed difference in lactates from the US study is due to thi s 1166 laboratOJy assay problem causing all lactate levels to be reduced and the di ffcrcnces to be lessened, especially wi th higher serum concentrations of DCLI-I b. 77 Jahr ct al. found that the average di ffercnce between measured and calculated (actual) lactate levels could be an underestimation of between -2.2 mg/dL and -12 mg/dL when measured in the presence of an oxidizing hemoglobin agent outside the protective red blood cell . At cl inically relevant concentrations of HBOC infusions ( 1-2 g/dL), the average difference was -2.2 mg/dL. This work is consistent with the BP analysis from these two DCHLb clinical trials, which suggests the lack of an adverse pressor effect as seen by the absence of consistently or markedly elevated BP values with DCLHb resuscitation.14·22 Several important facts were observed in the DCLHb BP publication. Although mean SBP and diastolic BP values differed at 2 of the I 0 measured time points, BP curve analysis showed no SBP, diastolic BP, or mean arterial pressure differences based on treatment. Although SBP values ~160 and ~120 mm Hg were 2.2X and 2.6X more frequently noted in survivors, they were not more common with DCLHb use, nor in DCLHb patients who expired, in US study nonsurvivors, or in any EU study patients. SBP values ~160 and ~120 nun Hg were 2.8X and 1.3X more frequently noted in DCLHb survivors when compared with NS survivors. Only 3% of the BP variation noted could be attributed to DCLHb use, and as expected, injury severity and baseline physiologic status were stronger predictors. 18 It is noteworthy that the times at which these BD and lactate values were obtained varied substantially, reflecting the variable clinical use of these laboratory tests, even in clinical trials. 8 • 16 This time variability is not thought to have caused the study of potential adverse perfusion effects to be altered in a way that renders the conclusions of this post-hoc analysis to be erroneous.
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It has been suggested that the real adverse consequences of the proposed pressor effects associated with HBOC use in trauma resuscitation are the possibility that elevated BP may cause clots to be disrupted, leading to accelerated hemorrhage and higher mortality. 20 Two findings are of note from these DCLHb clinical trials. First, markedly elevated BPs were neither uniquely observed in patients treated with DCLHb nor was mortality related specifically to elevated BPs. 18 Second, analyses of hemorrhage adverse events and severe adverse events at the time that these clinical trials were halted did not demonstrate a greater frequency of hemorrhagic complications in DCLHbtreated patients (unpublished data).
Further work will analyze the effect of DCLHb use in these clinical trials on the ability of the shock index (heart rate/SBP) to predict the need for continued resuscitation as well as its relationship with mortality. Preliminary data suggest that the performance of the shock index is not adversely affected by DCLHb use. 78 This shock index analysis will augment our understanding of how DCLHb and other HBOCs might improve patient outcomes due to being able to optimally fluid resuscitate trauma patients using readily available clinical parameters such as heart rate and SBP.
In summary, DCLHb, a tetrameric HBOC, was not associated with adverse perfusion as measured by BD and lactate data. This finding, when considered with the observation that there was not a measurable pressor effect or hemorrhage complications with DCLHb use, suggests that future study of HBOCs in the resuscitation of traumatic shock patients should not necessarily be prevented due to pressor effect concerns.
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